Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Rosa, AA; Carolina, AP; Marta, AV; Francisco, A; Adriana, FG; Natalia, G; Pablo, LL; Cristina, MF; Lydia, MS; Ulrike, N; Marina, S; Guillermo, HT; Henar, CG; Ana, GOD.

Experience of a Referral Center with Desmoid Tumors, Part 2: A Retrospective Analysis of 109 Cases

Cancers. 2026; 18(2): [doi:10.3390/cancers18020305]

López-Tarruella, S; Guerrero-Zotano, A; Antolín, S; Cruz, J; Martínez, P; Rodríguez, CA; Falo, C; Rodríguez-Lescure, A; Adrover, E; Hernández, M; Andrés, R; Chacón, JI; Romero, JLA; Miguel, A; Gómez-Raposo, C; Margelí, M; González, I; Guerra, JA; Antón, A; Tibau, A; Miralles, JJ; Escudero, MJ; Bezares, S; Rojo, F; Alvarez, I.

Clinical subtypes in breast cancer patients with brain metastases from an ambispective registry of advanced breast cancer, GEICAM/2014-03 (RegistEM)

Therapeutic Advances in Medical Oncology. 2026; 18: [doi:10.1177/17588359261421813]

de Andrea, CE; Abengozar-Muela, M; Arranz, JA; Climent, MA; Puente, J; Vizcay, A; de la Fuente, LM; Jurado, JM; Bonfill, T; Santander, C; Villa, JC; Pujol, E; Rosero, AC; Gomez, J; Fernández, EM; Fernández, CA; Ramirez, I; Arnáiz, P; López-Janeiro, A; Melero, I; Sanmamed, MF; Pérez-Gracia, JL.

Association of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients

OncoImmunology. 2025; 14(1): Nº de citas: 1 [doi:10.1080/2162402X.2025.2538687]

Cerezuela-Fuentes, P; Piñero-Madrona, A; Muñoz-Couselo, E; Manzano, JL; Berciano-Guerrero, MA; Majem, M; Espinosa, E; Soria, A; de Miguel, PA; Castaño, AG; Crespo, G; Sanz, LG; de la Rosa, CA; Fernández-Morales, LA; Puértolas, T; Rodríguez, JF; de la Borbolla, MR; Bellido, L; Castro, RL; Pérez, VN; Arroyo, FRG; Guzmán, JCV; Balea, BC; Hernández, B; Algarra, SM; Márquez-Rodas, I.

Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801

Clinical & Translational Oncology. 2025; : [doi:10.1007/s12094-025-04164-w]

Lopez-Jiménez, C; de Lucas, MB; de la Tabla, AGO; Alonso, NG; Arregui, M; Alvarez, R.

Primary Cardiac Sarcomas: Clinical Characteristics, Management, and Outcomes at a Spanish National Reference Center

Cancers. 2025; 17(24): [doi:10.3390/cancers17243947]

Pino-Roson, C; Avila-Arroyo, S; Parra-Blázquez, D; Zabalgogeazcoa, MJS; Moñino, D; Lopez-González, R; Sevilla-Hernández, C; González-Blázquez, C; Martín, M; Aragonés, N.

Breast cancer incidence and survival by subtype, stage at diagnosis and socioeconomic deprivation among young women in the Community of Madrid, Spain

INTERNATIONAL JOURNAL OF CANCER. 2025; 158(10): 2549-2559 [doi:10.1002/ijc.70278]

Jara, P; Ariant, M; Jiménez, R; Bringas, M; Herrero, B; Echavarría, I; Jerez, Y; Lopez-Tarruella, S; Márquez-Rodas, I; del Monte-Millán, M; Massarrah, T; de la Peña, FA; Martín, M.

Antitumor activity of the combination of vinorelbine and gemcitabine in patients with HR + /HER2-advanced breast cancer after CDK4/6 inhibitor

BREAST CANCER RESEARCH AND TREATMENT. 2025; 215(1): Nº de citas: 1 [doi:10.1007/s10549-025-07873-6]

Salazar, J; Arranz, MJ; Martin-Broto, J; Serra, M; Palmerini, E; Martínez-García, J; Juan-Ribelles, A; Andion, M; Martinez-Trufero, J; Gutiérrez, G; Echebarria-Barona, A; Vaz-Salgado, MA; Regueiro, A; Alvarez, R; Valverde, C; Luna, P; Blay, P; Sebio, A.

VEGF Signaling Pathway Germline Polymorphisms as Prognostic Pharmacogenetic Biomarkers in Localized High-Grade Osteosarcoma Patients from the GEIS-33 Protocol

Pharmaceuticals. 2025; 18(12): [doi:10.3390/ph18121855]

Cerezuela-Fuentes, P; de la Rosa, CA; Crespo, G; Berciano-Guerrero, MA; Soria, A; Muñoz-Couselo, E; Castro, RL; Majem, M; de Miguel, PA; Manzano, JL; Bellido, L; Lecumberri, MJ; Subias, MC; Guzmán, JCV; Hernández, B; Espinosa, E; Puértolas, T; Sanz, LG; Martínez, JM; Abril, VP; Algarra, SM; Márquez-Rodas, I.

Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study

MELANOMA RESEARCH. 2025; 35(6): 399-408 [doi:10.1097/CMR.0000000000001062]

Iglesias-Perez, C; Jimenez-Fonseca, P; Robles, JL; Adrián, SG; Pérez, IF; Prado, PMD; Pérez, JR; Castro, EMD; Pedroche, CD; Herreros, MGD; Campos, MC; Blanco, ABR; Fernández, MS; Verdúguez, TQ; González, DM; Rúa, MC; Crespo, JAS; Muñoz, MN; Muñoz, A; Carmona-Bayonas, A.

Venous thrombosis in lung cancer compared with other tumors: results from the TESEO-SEOM registry

THROMBOSIS RESEARCH. 2025; 256: [doi:10.1016/j.thromres.2025.109525]

Radosa, JC; Cobo, SLT; Dzieran, J; Glastetter, E; Chen, C; Lingohr-Smith, M; Pasupuleti, V; Brufsky, A.

Palbociclib treatment in patients with HR+/HER2-advanced or metastatic breast cancer and visceral metastasis: A systematic literature review

BREAST. 2025; 84: [doi:10.1016/j.breast.2025.104569]

de la Peña, FA; Novoa, SA; Gregori, JG; Cortijo, LG; Carrasco, FH; Martínez, MTM; Estévez, CM; Stradella, A; Losada, MJV; Ciruelos, E.

SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025)

Clinical & Translational Oncology. 2025; 28(1): 105-125 Nº de citas: 1 [doi:10.1007/s12094-025-04139-x]

Espinosa, E; Berciano-Guerrero, MA; Muñoz-Couselo, E; Puértolas, T; Manzano, JL; Soria, A; De Miguel, PA; Crespo, G; Sanz, LG; Cerezuela-Fuentes, P; de la Rosa, CA; Majem, M; Castaño, AG; Berrocal, A; Arroyo, FRG; de la Borbolla, MR; Bellido, L; Martínez, JM; Fernández, LA; Carnicero, AM; Castro, RL; Rodríguez, AB; Lecumberri, MJ; Guzmán, JCV; Balea, BC; Rodríguez, JF; Bautista, JV; Pérez, VN; Mujika, K; Subias, MC; Hernández, B; Algarra, SM; Márquez-Rodas, I.

Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801

Clinical & Translational Oncology. 2025; : [doi:10.1007/s12094-025-04098-3]

Salgado, M; de la Camara-Gomez, J; García-Escobar, I; Alvarez-Llosa, RC; González-Villarroel, P; Garay, DF; Pàmpols-Felip, M; Guillot-Morales, M; Pelegrín-Mateo, FJ; Jimenez-Orozco, E; Sastre, J; De Castro, EM; Coma, E; Bouzas, LP; Ferrer-Pérez, AI; Mompradé-Olivé, E; Cousillas-Castiñeiras, A; Covela-Rúa, M; Rojas, M; Querol, R; Díaz, LR; Merino, M; Gil, M; Sánchez-Cánovas, M; Elías, T; Marrupe-González, D; Sánchez-Gil, B; Carmona-Campos, M; García-Ferron, M; Soria, JM; Muñoz, A.

Tinzaparin for the prevention of thromboembolic events in ambulatory patients with metastatic colorectal cancer receiving first line treatment: a randomised, clinical trial design

BMC CANCER. 2025; 25(1): [doi:10.1186/s12885-025-14620-z]

Verrill, M; Lux, MP; Gligorov, J; Geisler, J; Duchnowska, R; Elsberger, B; Martin, M.

Genomic tests to guide management of breast cancer in Europe: regulation, reimbursement, adoption, and challenges

Future Oncology. 2025; 21(27): 3573-3583 Nº de citas: 1 [doi:10.1080/14796694.2025.2577335]

Masini, S; Basa, MA; Calles, A; Cabellos, RA; Echebarria, ID; Puchol, CT; Kareaga, MM; Cabezon-Gutierrez, L; Perez, MCE; Lage, Y; Lorenzo, EG; Navarro, F; Sereno, M; Martínez, SF; García-Benito, C; Pinto, LM; Andrade, CA; Sequero, S; Martinez, JM; Lopez-Martín, A; Martínez, AA; Martín-Soberon, MC; Lucia-Gozalvez, C; Rubio, J; Tallafigo, L; Garrido, A; Peressini, M; Torres-Jimenez, J; Zurera, M; Bote, H; Ponce, S; Paz-Ares, L; Zugazagoitia, J; Baena, J.

Real-World Data of First-Line Cemiplimab Monotherapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) with PD-L1 Expression = 50%: A National Spanish Multicentric Cohort (CEMI-SPA Study)

Cancers. 2025; 17(22): [doi:10.3390/cancers17223643]

Garcia-Saenz, JA; Lopez-Barajas, IB; Echavarria, I; Gonzalez, CH; Vila, MM; Antón, FM; Pernas, S; Cajal, TRY; Ribelles, N; Ezquerra, MB.

SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025)

Clinical & Translational Oncology. 2025; 28(1): 126-147 Nº de citas: 2 [doi:10.1007/s12094-025-04102-w]

Crown, J; Stroyakovskii, D; Huang, CS; Yardley, DA; Fasching, PA; Bardia, A; Chia, S; Im, SA; Martin, M; Xu, B; Barrios, CH; Untch, M; Moroose, R; Hurvitz, SA; Hortobagyi, GN; Slamon, DJ; Visco, F; Spera, G; Zarate, JP; Halligan, D; Li, Z; Loi, S.

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year followup of NATALEE efficacy outcomes and updated overall survival

ESMO Open. 2025; 10(11): Nº de citas: 13 [doi:10.1016/j.esmoop.2025.105858]